Xencor Shares Rise 17% Following Announcement of Oral Presentation Slot at ESMO 2026

Shares of Xencor (NASDAQ: XNCR) rose by 17%, closing at $17.47, after the company announced an oral presentation slot for its Phase 1 clinical study on XmAb819 in advanced clear cell renal cell carcinoma at ESMO 2026.

By SA News, SA News Editor · Seeking Alpha · July 17, 2026, 20:50 UTC

Tickers: $XNCR

Topics: biotech cancer research stock movement

Read the full article at Seeking Alpha

More World news

AiPrise Launches Token Sharing Infrastructure to Streamline Compliance Verification PR Newswire · November 12, 2026, 19:39 UTC
Barclays Upgrades Steel Producers Cleveland-Cliffs and Reliance Amid Market Selloff Seeking Alpha · November 12, 2026, 19:32 UTC
Mercantile Bank Announces New Full-Service Banking Center in Holland, Michigan PR Newswire · November 12, 2026, 19:28 UTC
Broadwind Reports 48% Revenue Growth and Record Industrial Solutions Backlog in Q3 2026 Motley Fool · November 12, 2026, 19:25 UTC
MediWound Reports Q3 2026 Financial Results Amid Clinical Trial Expansion Motley Fool · November 12, 2026, 19:25 UTC
Twist Bioscience Reports Q4 2026 Revenue Growth and First Positive Adjusted EBITDA Motley Fool · November 12, 2026, 19:25 UTC
Chicago Atlantic BDC Reports Q3 2026 Growth in Net Investment Income and Record Portfolio Value Motley Fool · November 12, 2026, 19:25 UTC
Google Integrates Gemini 4 Hydrogen Model into Search to Enhance Complex Query Handling TechCrunch · November 12, 2026, 19:27 UTC
General Motors Partners with NorthStar Clean Energy for Large-Scale Solar Project in Michigan Seeking Alpha · November 12, 2026, 19:24 UTC
CNBC Select Names Accredited Debt Relief Best for Debt Resources PR Newswire · November 12, 2026, 19:25 UTC